Good News for a Small-Cap Imaging Company
Schering AG's purchase of Diatide Inc. appears to be an exception to the general rule that, while small-cap acquisitions are at an all-time high, the shareholders of acquired companies don't fare particularly well. Schering areed to pay a significant premium over the the Diatide stock price just prior to the deal, despite the fact that Nycomed Amersham PLC owns partial rights to Diatides two late-stage products. Schering was willing to pay the price because of its commitment to developing a franchise in nuclear imaging.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month
France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.